Regenerex Pharma (RGPX) Free Cash Flow (2011 - 2025)

Regenerex Pharma (RGPX) has 13 years of Free Cash Flow data on file, last reported at -$519355.0 in Q3 2025.

• Free Cash Flow for Q3 2025 came in at -$519355.0, down 310.21% year-over-year; the trailing twelve-month figure through Sep 2025 was -$2.4 million (down 605.0% YoY), and the FY2025 annual result was -$1.6 million, down 250.67% from the prior year.
• Free Cash Flow eased to -$519355.0 in Q3 2025 per RGPX's latest filing, from -$477943.0 in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1362.0 in Q1 2022 and troughed at -$1.3 million in Q1 2025.
• A 5-year average of -$179448.4 and a median of -$59883.5 in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 66.56% in 2022, then sank 2030.79% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$20593.0 in 2021, then tumbled by 39.02% to -$28628.0 in 2022, then sank by 248.7% to -$99827.0 in 2023, then plunged by 58.99% to -$158713.0 in 2024, then slumped by 227.23% to -$519355.0 in 2025.
• Business Quant data shows RGPX's Free Cash Flow at -$519355.0 in Q3 2025, -$477943.0 in Q2 2025, and -$1.3 million in Q1 2025.